News-US Phase II Trials

[Guest guest]

NEWS-US Phase II Paclitaxel+Carboplatin 20-Jun-08 03:13 am

http://biz./prnews/080620/to390...

Dr. Mita the PI of the Sarcoma trial will be Principal Investigator of

this new trial as well.

" The Principal Investigator is Dr. Mita of the Cancer Therapy

and Research Center,University of Texas Health Science Center in San

, Texas (CTRC atUTHSCSA). "

" This trial is a 14-patient, single arm, open-label, dose-targeted, non-

randomized trial of REOLYSIN® given intravenously in combination with

a standard dosage of paclitaxel and carboplatin

Eligible patients include those with advanced or metastatic head and

neck cancers that are refractory to standard therapy or for which no

curative standard therapy exists. "

[Guest guest]

>

> NEWS-US Phase II Paclitaxel+Carboplatin 20-Jun-08 03:13 am

> http://biz./prnews/080620/to390...

> Dr. Mita the PI of the Sarcoma trial will be Principal Investigator

of

> this new trial as well.

>

> " The Principal Investigator is Dr. Mita of the Cancer

Therapy

> and Research Center,University of Texas Health Science Center in

San

> , Texas (CTRC atUTHSCSA). "

>

> " This trial is a 14-patient, single arm, open-label, dose-targeted,

non-

> randomized trial of REOLYSIN® given intravenously in combination

with

> a standard dosage of paclitaxel and carboplatin

> Eligible patients include those with advanced or metastatic head

and

> neck cancers that are refractory to standard therapy or for which

no

> curative standard therapy exists. "

>

YES 20-Jun-08 09:28 am " " REOLYSIN® is one of the more

exciting targeted agents under development in oncology, " said Dr.

Giles, Director of the Institute for Drug Development. " Our

investigators within the CTRC at UTHSCSA are very excited to begin

studying potential synergy with standard cytotoxic agents and are

eager to expand our studies into other tumor types and utilizing

other chemotherapy partner regimens. " "